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Abstract.  Neurons and endocrine cells have two types 
of secretory vesicle that undergo regulated exocytosis. 
Large dense core vesicles (LDCVs) store neural pep- 
tides whereas small clear synaptic vesicles store clas- 
sical neurotransmitters such as acetylcholine, "r-amino- 
butyric acid (GABA),  glycine, and glutamate. 
However,  monoamines differ from other classical 
transmitters and have been reported to appear in both 
LDCVs and smaller vesicles.  To localize the trans- 
porter that packages monoamines into secretory vesi- 
cles, we have raised antibodies to a COOH-terminal 
sequence from the vesicular amine transporter ex- 
pressed in the adrenal gland (VMAT1). Like synaptic 
vesicle proteins, the transporter occurs in endosomes 
of transfected CHO cells, accounting for the observed 
vesicular transport activity.  In rat pheochromocytoma 
PC12 cells, the transporter occurs principally in 
LDCVs by both immunofluorescence and density gra- 
dient centrifugation. Synaptic-like microvesicles in 
PC12 cells contain relatively little VMAT1. The results 
appear to account for the storage of monoamines by 
LDCVs in the adrenal medulla and indicate that 
VMAT1 provides a novel membrane protein marker 
unique to LDCVs. 
N 
EUROTRANSMITTERS are stored in secretory vesicles 
that undergo regulated exocytosis. Peptide transmit- 
ters enter the secretory  compartment  by co-trans- 
lational translocation of a precursor protein into the lumen 
of  the endoplasmic reticulum and subsequently undergo pro- 
cessing and packaging into mature vesicles (de Camilli and 
Jahn, 1990; Trimble et al., 1991; Kelly, 1991). In contrast, 
the synthesis of classical transmitters such as acetylcholine, 
3'-aminobutyric acid (GABA),t glycine, glutamate, and the 
biogenic amines occurs in the cytoplasm. These transmitters 
also appear in the cytoplasm after removal from the synapse 
by specific plasma membrane reuptake systems (Amara and 
Kuhar,  1993). Thus, classical transmitters  require  specific 
transport  from the cytoplasm for packaging into secretory 
vesicles. In addition, the storage of neural peptides and clas- 
sical transmitters occurs in distinct vesicle populations. 
Address all correspondence to R. H. Edwards,  Department of Neurology, 
UCLA School of Medicine, 710 Westv,  x~xl Blvd., Los Angeles, CA 90024- 
1769. Ph.: (310) 206-7672.  Fax:  (310) 206-2502. 
1. Abbreviations  used in this paper: CGAT, chromaflin  granule amine trans- 
porter; DBH, doparnine #-hydroxylase;  DFP, diisopropylfluorophosphate; 
GABA, 3,-aminobutyric  acid; HBS, Hepes-buffered  saline; KLH, keyhole 
limpet hemocyanin; LDCV, large dense core vesicles; MBS, m-maleimido- 
benzoyl  N-hydroxysuccinimide;  MPP  +,  N-methyl-4-phenylpyridinium; 
mppres, Mpp  + resistant; NGS, normal goat serum; PAM, peptidylglycine 
c~-amidating monooxygenase;  VMAT1, vesicular amine transporter. 
Neural cells store peptide transmitters in large dense core 
vesicles (LDCVs), the functional equivalent of the secretory 
granules in which endocrine cells store peptide hormones 
(Kelly, 1991; Trimble et al., 1991). These granules range in 
size from 40 to over 100 nm and have a characteristic dense 
core in electron micrographs, presumably due to their pro- 
tein content. LDCVs also have a relatively diffuse distribu- 
tion in the cytoplasm. They appear in nerve terminals but not 
at the same high density as classical synaptic vesicles; they 
also occur in the cell body and dendrites. In contrast,  neu- 
rons  store  classical  transmitters  such  as  acetylcholine, 
GABA, glycine, and glutamate in small clear synaptic vesi- 
cles of 40-50 nm (Sudhof and Jahn,  1991; Edwards, 1992). 
Typical  synaptic vesicles cluster  in large numbers  at the 
nerve terminal,  in close proximity to the presynaptic mem- 
brane. In addition to these differences in structure and local- 
ization, large dense core vesicles and synaptic vesicles also 
differ in function.  Exocytosis from LDCVs occurs  with a 
longer latency after stimulation than exocytosis from synap- 
tic  vesicles  (de  Camilli  and Jahn,  1990). The  observed 
differences in rate of  release presumably account for the rela- 
tively prolonged action of peptides as neural modulators and 
the more rapid action of classical neurotransmitters in direct 
signaling. In addition, high frequency stimulation favors re- 
lease from LDCVs relative to synaptic vesicles (Andersson 
et al.,  1982). Differential sensitivity to u-latrotoxin  (Mat- 
teoli et al.,  1988), and intracellular  calcium (Rane et al., 
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exocytosis from the two types of vesicle involves  distinct 
mechanisms.  Thus,  the  storage  of peptide  and  classical 
transmitters in different vesicular compartments has clear 
implications for the regulation of their release and for their 
role in synaptic transmission. Since the packaging of classi- 
cal  transmitters into vesicles  requires  transport  from the 
cytoplasm, the selective packaging of specific  transmitters 
into different types of vesicles depends on the expression of 
specific transport activities by these different vesicles. 
Previous studies have identified at least four distinct vesic- 
ular transport activities: one for the biogenic amines, a sec- 
ond for acetylcholine, another for GABA and glycine and a 
fourth  for  glutamate  (Sudhof and  Jahn,  1991; Edwards, 
1992).  The availability of bovine adrenal chromaffin gran- 
ules and their robust transport activity have made the vesicu- 
lar transport of monoamines a prototype for vesicular neu- 
rotransmitter transport. Studies using this preparation have 
shown  that  vesicular  amine  transport  depends  on  a  pH 
gradient  generated  by  the  vesicular  H+-ATPase  (Kanner 
and Schuldiner, 1987; Johnson, 1988).  The transporter ex- 
changes two lumenal protons for a cytoplasmic amine. Re- 
cent studies have shown that the vesicular transporters for 
other classical transmitters depend on different aspects of the 
same H+-electrochemical gradient (Anderson et al.,  1982; 
Maycox et al.,  1988; Hell et al., 1990).  However, classical 
transmitters do not all appear to be stored in the same vesicu- 
lar compartment.  Typical small synaptic vesicles express 
specific transport activities for acetylcholine, GABA, gly- 
cine, and glutamate, consistent with storage in this compart- 
ment (Burger et al.,  1989).  On the other hand, cells in the 
adrenal medulla store monoamines with neural peptides in 
large dense core chromaffin granules (Johnson, 1988). In the 
central nervous system, neurons store monoamines in small 
vesicles that may contain a  dense core depending on the 
method of fixation (Smith,  1972;  Thureson-Klein,  1983). 
Thus, the storage of monoamines appears to differ from that 
of other classical transmitters and presumably reflects  the 
differential sorting of vesicular transport proteins. 
Using selection in the neurotoxin N-methyl-4-phenylpyri- 
dinium (MPP÷),  we have recently cloned a eDNA encoding 
the chromaffin granule amine transporter (CGAT) or vesicu- 
lar amine transporter (VMAT1) (Liu et al., 1992b; Erickson 
et al.,  1992).  The transporter protects against this toxin by 
sequestering it in intracellular vesicles, away from its pri- 
mary site of action in mitochondria (Liu et al., 1992a).  The 
sequence predicts a protein with twelve transmembrane do- 
mains and weak homology to several bacterial antibiotic re- 
sistance transporters (Liu et al., 1992b).  We have now used 
the amino acid sequence deduced from this eDNA to design 
a synthetic peptide, produce polyclonal antisera to the trans- 
porter and determine its intracellular location. The results 
indicate expression of the transporter in endocytic vesicles 
of CHO fibroblasts and preferential expression in LDCVs of 
neuro-endocrine PC12  cells. 
Material and Methods 
Cell Culture 
CHO cells were maintained in Ham's F-12 medium with 5% FCS and rat 
pheochromocytoma PC12 cells in modified DME with 10%  horse serum 
and 5% FCS. All cultures were kept at 37°C in 5% CO2 and all media con- 
tained penicillin and streptomycin. 
CHO  cells  were  co-transfected as  previously described (Liu  et  al., 
1992a)  with 10 #g of the VMATI eDNA in the plasmid expression vector 
CDM8 and  1 ttg of the selectable marker Rous sarcoma virus-neomycin 
(RSV-neo) per 10 cm plate. After initial  selection in 400 #g/ml G418 for 
2  wk,  the cells were selected again in  1 mM MPP  + for at  least 3  wk. 
MPP+-resistant (mpp  res) cells were maintained in the absence of the toxin 
for at least 1 wk before study. 
To label the dense core granules with [3H]norepinephrine, PCI2 cells 
were incubated in standard medium containing 5 #Ci  [3H]noradrenaline 
(Amersham Corp., Arlington Heights, IL)/25 ml for at least 6 h before cell 
fractionation. 
Peptide Synthesis and Antibody Production 
The peptide CGENSDDPSSGE was synthesized manually and coupled to 
keyhole  limpet  hemocyanin  (KLH)  through  the  NH2-terminal  cysteine 
using m-maleimidobenzoyl N-hydroxysuccinimide ester (MBS).  For the 
primary inoculation,  150 #g of the conjugated peptide was emulsified in 
complete Freund's adjuvant and injected intradermally into adult female 
rabbits (Harlow and Lane,  1988).  Antibody production was boosted 4 wk 
later by the subcutaneous injection of 100/~g conjugated peptide emulsified 
in incomplete Freund's adjuvant. After 12 d, the animals were bled through 
an ear vein. The antibody titer following the first boost was then measured 
using the unconjugated peptide in a solid-phase ELISA (Harlow and Lane, 
1988).  Animals making anti-peptide antibodies were then boosted further 
with 100 p,g of conjugated peptide at 4-wk intervals, with serum collected 
2 wk after each boost. The anti-peptide antibodies were purified on a pep- 
tide  affinity  column of epoxy-activated Sepharose 6B  (Pharmacia  Fine 
Chemicals, Piscataway, NJ). For adsorption, the antibody was diluted 1:100 
in 500 #10.1% Tween-20/PBS, 0.5 mg peptide added, the mixture incubated 
overnight at 4°C, and then diluted further in the same solution for immuno- 
staining. 
Immunostaining 
For immunocytocherrtistry, cells cultured overnight in a 24-well plate were 
fixed in 4% paraformaldehyde/0.1 M PBS, pH 7.2, permeabilized in 0.2% 
Triton X-100/PBS for 15 rain and blocked with 5% nonfat dry milk in PBS 
for 30 rain at room temperature. The cells were then incubated for 60 rain 
with  the  primary  antibody  diluted  1:1,000-1:5,000  in  1%  nonfat  dry 
milk/PBS and washed three times in PBS, each for 5 rain. Incubation in a 
secondary biotinylated anti-rabbit antibody (Vector Labs, Burlingame, CA) 
was also carried out for 30 rain, followed by three 5-rain washes in PBS. 
The complexes were visualized using avidin-biotin conjugated to alkaline 
phosphatase (Vector Labs). 
For immunocytochemistry of the adrenal gland, adult,  male Sprague- 
Dawley rats were anesthetized with sodium pentobarbital (50 mg/kg i.p.) 
and perfused through the ascending aorta with 4% paraformaldehyde/0.1 M 
sodium phosphate, pH 7.2. The adrenal gland was then dissected, postfixed 
again in the same solution for an additional hour at room temperature, in- 
cubated in 30% sucrose at 4°C overnight, frozen, sectioned at 10 #m, and 
the tissue collected on gelatin-coated slides for immunocytochemistry as 
described above. 
For immunofluorescence,  both CHO and PCI2 cells were grown on glass 
coverslips to 60-80%  confluence and processed as described (Schweitzer 
and  Paddock,  1990).  PC12  cells were treated  with  10  ng/ml  NGF  in 
medium containing serum for four days before staining. The cells were then 
fixed as  described above,  permeabilized  in  0.1%  Triton  X-100/Hepes- 
buffered saline  (HBS),  and  then  incubated  with  anti-peptide antibody 
diluted 1:1,000 in  1%  normal goat serum (NGS)/HBS.  After washing in 
HBS, the cells were incubated at room temperature with goat anti-rabbit 
antibody conjugated to fluorescein diluted 1:100 in 1% NGS/HBS, washed 
again, and visualized with epifluorescence. Double staining with WGA con- 
jugated to Texas red and monoclonal antibodies to tubulin, secretogranin 
I, and synaptophysin was carried out simultaneously. The mouse antibodies 
were visualized by incubation with a biotinylated sheep anti-mouse anti- 
body followed by streptavidin-Texas red (Amersham Corp.). 
To identify transferrin receptors, the CHO cells were pre-incubated in 
serum-free medium at 37°C for 60 min to remove endogenous transferrin, 
incubated with 20 #g/ml human transferrin conjugated to Texas red (Molec- 
ular Probes, Eugene, OR) for an additional 30 min, rinsed quickly in cold 
medium without transferrin, and then fixed and the cells examined under 
epifluorescence. 
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Cell membranes were prepared as described previously (Liu et al., 1992b). 
Briefly,  cells rinsed twice in cold FIBS containing 5 mM MgEGTA were 
detached from the substrate by scraping in FIBS with EGTA supplemented 
by 1 t~g/ml leupeptin and 0.2 mM diisopropylfluoro-phosphate  (DFP). The 
cells were then homogenized by repeated passage through a ball-beating de- 
vice (European Molecular Biology Labs, Heidelberg, Germany) at a clear- 
ante of 10/~m. The nuclei and other cell debris were pelleted by centrifuga- 
tion  at  750  g  for 5  min.  To  prepare membranes, the supernatant was 
centrifuged again at 35,000 rpm in a Beckman SW50.1 for 45 rain at 4"C 
and the pellet resuspended in either FIBS or electrophoresis sample buffer 
(67.5 mM Tris, pH 6.8, 3% SDS, 10% glycerol, 5% 2-mereaptoethanol). 
For cell fractionation by equilibrium sedimentation, the postnuclear su- 
pernatant was layered onto a linear 0.6-1.6  M sucrose gradient in 10 mM 
Hepes for sedimentation at 30,000 rpm for 6 h in an SW41 rotor (Beckman 
Instruments, Palo Alto, CA) at 4°C. Fractions were collected from the bot- 
tom of the tube and stored at -70"C. The protein content was monitored 
using the Bradford assay (Bio-Rad Laboratories, Richmond, CA) and the 
radioactivity of fractions from ceils pre-loaded with [3H]norepinephrine 
measured in Eeolume (ICN Biomedicals, Irvine, CA) using a  Beckman 
3800 scintillation counter. 
For velocity sedimentation through glycerol, the post-nuclear superna- 
tant was centrifuged in a SW50.1 (Beckman Instruments) at 48,000 rpm for 
1 h at 4"C through 5-25 % glycerol in FIBS containing 1 mM EGTA (Clift- 
O'Grady et al., 1990) and the fractions processed as described above. FOr 
metrizamide gradients, the postnuclear supernatant from ceils disrupted in 
0.32 M sucrose/4 mM Hepes, pH 7.4/0.5  mM EDTA (SH buffer) was cen- 
trifuged for 2.25 h at 55,000 rpm in a 70.1 Ti rotor (Beckman Instruments) 
through 10-23 % metrizamide over a cushion of 35 % metrizamide, with the 
10 and 23%  stock solutions of metrizamide prepared by dilution of 35% 
metrizamide with SH buffer (Green et al.,  1994),  and the fractions pro- 
cessed in the same way as the other gradients. 
Gel Electrophoresis and Western Blot Analysis 
Postnuclear supernatants and aliquots from fractions of  the sucrose gradient 
were diluted in 2 x  sample buffer and separated by electrophoresis through 
10%  SDS-polyacrylamide containing 6  M  urea. The resulting gels were 
transferred to nitrocellulose (BA-S NC; Schleicher & Schuell) using a semi- 
dry electrotransfer apparatus (E&K Scientific Products Inc., Saratoga, CA). 
Aliquots from the metrizamide and glycerol gradients were immobilized on 
nitrocellulose dot blots.  The filters were then blocked in 0.1%  Tween- 
20/PBS (TBS) containing 5% nonfat dry milk, incubated in primary anti- 
body for 60 min in TBS with 1% nonfat dry milk, washed three times in 
TBS and then incubated with secondary antibody conjugated to peroxidase. 
The immune complexes were visualized by chemiluminescence (Amersham 
Corp.) and quantitated by densitometry. 
Metabolic Labeling and Immunoprecipitation 
CHO and PCI2 cells at moderately high density were metabolically labeled 
with [3SS]cysteine and methionine (Translabel; ICN Biomedicals) at 0.25 
mCi/ml in cysteine- and methionine-free  medium supplemented by 1% dia- 
lyze,  d FCS. When indicated, tunicamycin was added at 20 ng/ml to inhibit 
N-linked glycosylation. After labeling for 6 to 12 h, the cells were rinsed 
with PBS, detached from the substrate by scraping in 1% sodium deoxycho- 
late,  1%  Triton X-100, 0.2%  SDS,  150 mM NaCI,  50 mM Tris, pH 7.4 
(RIPA buffer) containing 20 p.g/ml PMSE and the nuclear debris removed 
by centrifugation. 
For immunoprecipitation, the resuspended ceils were diluted to a final 
volume of 1 ml RIPA and incubated overnight at 4°C with afffinity-purified 
anti-peptide antibody at a dilution of 1:1,000. The antigen-antibody com- 
plexes were precipitated by incubation for 4  h  at 4°C with 200 #1  10% 
prewashed protein A sepharose (Sigma Chemical Co., St. Louis, MO) and 
the precipitates washed three times in RIPA (Edwards et al.,  1988).  The 
beads were then resuspended in 50 #12 x  sample buffer and 25 t~l separated 
by electrophoresis  through 10% SDS-polyacrylarnide containing 6 M urea. 
After electrophoresis at  10-25  mA,  the gels were fixed in  10%  acetic 
acid/50%  methanol for 20 min, impregnated with 1 M  sodium salicylate 
for 20 rain, dried, and exposed to film at -70°C with an enhancing screen. 
N-Glycanase Digestion 
For N-glycanase digestion, the immunoprecipitate obtained as described 
above from PC12 cells metabolically labeled with [3SS]cysteine and methi- 
onine was resuspended in 0.5%  SDS/50 mM fl-mercaptoethanol/50 mM 
NaPO4, pH 8. 20 t~g protein was then digested with 0.3 U of N-glycanase 
(G-enzyme Corp., Boston, MA) in the presence or absence of 1.2% NP-40 
at 37°C overnight, the reaction stopped by dilution in sample buffer,  and 
the products analyzed by electropboresis through polyacrylamide contain- 
ing SDS. 
Immunoisolation 
Fixed S. aureus cells were pre-coated with: (a) rabbit VMATI anti-peptide 
antibody; and (b) rabbit anti-goat antisera as control by incubation with 
gentle rotation in 150 mM NaCI,  10 mM Hepes, pH 7.4,  1 mM EGTA, 
1 mM MgCl2,  1%  BSA (buffer A) for 2  h  at 4°C.  The cells were then 
washed three times in buffer A and incubated with postnuclear supernatants 
containing ",,30,000  dpm from PCI2  cells pre-labeled with [3H]norepi- 
nephrine as described above. For immunoisolation with the SV2 antibody, 
Staphylococcus  aureus cells were pre-coated first with a rabbit anti-mouse 
antibody; then with (c) mouse SV2 monoclonal antibody; and (d) normal 
mouse serum as control. After incubation of the cell extracts with the pre- 
coated beads for 2 h at 40C, the mixtures were precipitated by centrifugation 
at 1,000 g and the radioactivity in the supernatant determined by liquid scin- 
tillation counting. Subtraction of the radioactivity in the supernatant from 
the total radioactivity yielded the radioactivity in the immunoprecipitated 
vesicles. 
Immunoelectron Microscopy 
Methods for tissue preparation and immunolabeling were based on those 
described by Leranth and Pickel (1989).  Adult male Sprague-Dawley rats 
(250-350 g) were anesthetized as described above with sodium pentobarbi- 
tal and perfused with 40 ml heparinized saline (l,000 U/ml beparin in 0.15 
M NaCl) followed by 50 ml 3.75 % acrolein and then by 200 ml 2 % parafor- 
maldehyde/0.1  M sodium phosphate, pH 7.4.  The adrenal glands were re- 
moved, postfixed in 3.75% acrolein for 30 min and sections cut on a vibra- 
tome at 40 #m. The sections were then incubated for 30 min in 1% sodium 
borohydride/0.1  M sodium phosphate, pH 7.4 to remove reactive aldehydes 
and rinsed repeatedly in 0.1 M sodium phosphate, pH 7.4. The sections were 
cryo-protected for 15 min in 25%  sucrose/3.5% glycerol/0.05 M  sodium 
phosphate, pH 7.4 and rapidly freeze-thawed in chlorodifluoromethane fol- 
lowed by liquid nitrogen. 
Sections were incubated in anti-VMAT1  antibody diluted  !:12,000  in 
0.1%  BSA/0.15  M  NaCI/25  mM Tris,  pH 7.6, and the bound antibodies 
identified with an avidin-biotin complex (Hsu et al., 1981). Briefly, the sec- 
tions were incubated first for 30 min in a 1:50 dilution of biotinylated goat 
anti-rabbit IgG in 0.1% BSA and then for 30 rain in a l:100 dilution of the 
peroxidase-avidin-biotin  complex. The tissue was then incubated for 6 min 
in Tris-buffered saline containing diaminobenzidine and hydrogen peroxide 
to visualize the bound peroxidase. 
Sections were fixed in 2% osmium tetroxide for 60 min and fiat embed- 
ded in Epon 812  between two pieces of Aclar plastic. Ultrathin sections 
were collected from the outer surface of the plastic-embedded tissue using 
an RMC ultramicrotome, counterstained with lead citrate, and examined 
using a Phillips 201  electron microscope. 
Results 
Production and Characterization of VMAT1 Antibody 
Although the sequence of  VMAT1 indicates an extremely hy- 
drophobic  protein  with  12  predicted  transmembrane  do- 
mains and few antigenic regions, we synthesized a 16-amino 
acid peptide from the relatively hydrophilic COOH terminus 
and added a cysteine to the NH2 terminus of the sequence 
for coupling through MBS to the carrier KLH. After immu- 
nization, rabbit sera were screened for the presence of anti- 
bodies  using  a  peptide  ELISA.  Animals  producing  anti- 
bodies to the peptide were boosted again and their sera tested 
further by immunostaining MPP  + resistant CHO cells trans- 
fected with the VMAT1  eDNA (Liu et al.,  1992b). 
The antisera from one rabbit recognized the VMAT1 pro- 
tein in transfected but not wild-type CHO cells (Fig. 1). The 
Liu et al.  Vesicular Transporter in Secretory Granules  1421 Figure 1. Immunostaining with an anti-peptide antibody shows a particulate cytoplasmic pattern of VMAT1 expression in transfected CHO 
fibroblasts. CHO cells transfected with the VMAT1 cDNA and selected in MPP+ (a and b) and untransfected wild-type CHO cells (c 
and d) were immunostained with an anti-peptide antibody to VMAT1 at a dilution of 1:2,000 and visualized by phase contrast (a and c) 
and epi-fluorescence (b and d). The transfected cells show a particulate pattern of cytoplasmic fluorescence very similar to that seen previ- 
ously for pre-loaded dopamine (Liu et al., 1992a), whereas wild-type cells show no immunoreactivity. Comparison of the phase contrast 
and fluorescence micrographs shows that the focal concentration of fluorescence observed in transfected cells is outside of but adjacent 
to the nuclei. Bar, 10 #m. 
perinuclear and  scattered particulate cytoplasmic staining 
strongly  resembled the  distribution  of intracellular dopa- 
mine  observed  after  loading  these  same  MPP+-resistant 
cells with exogenous dopamine (Liu et al., 1992a). To char- 
acterize the antibody further, we tested its ability to detect 
VMAT1 by Western blotting (Fig. 2). Wild-type CHO cells 
expressed no immunoreactive protein whereas transfected 
MPP+-resistant  cells expressed large amounts of an ,055- 
kD protein and smaller but still substantial amounts of an 
,095-kD protein. Rat pheochromocytoma PC12 cells, from 
which  the  VMAT1  cDNA  originally  derived,  expressed 
small amounts of the 55-kD protein, and variable amounts 
of a higher molecular weight form of ,0120 kD. In both cell 
types the size differed from previous work indicating a pro- 
tein of ,075 kD in bovine chromaffin granules (Stern-Bach 
et al.,  1990; Vincent and Near, 1991; Isambert et al.,  1992) 
but the species origin of the cDNA from rat and the use of 
urea in the gel system may alter the electrophoretic mobility 
of this extremely hydrophobic protein. In addition, previous 
studies have concentrated on one of the two transport iso- 
forms  separated  by  isoelectric  focusing  (Stern-Bach  et 
al.,  1990). The differences in amount of VMATI expressed 
by the different cells are consistent with variations in the 
amount  of VMAT1  mRNA  previously observed in  CHO 
transfectants and PC12 cells (Liu et al., 1992b). In addition, 
adsorption of the antibody with the peptide eliminated these 
immunoreactive species on Western blots (data not shown). 
Although the antisera had a titer of 1:1,000-1:2,000 and pro- 
duced  relatively  low  background  staining  in  transfected 
cells, the antibody was further purified on a peptide affinity 
column (Pharmacia Biotech Inc.) and used at a dilution of 
1:10,000-1:20,000. 
To characterize the ability of the anti-peptide antibody to 
recognize VMAT1 in vivo, we have also used the antiserum 
to immunostain sections of the rat adrenal gland.  Fig.  3 a 
shows  strong  staining  of chromaffin cells  in  the  adrenal 
medulla and no staining of cortical cells. As expected for a 
vesicle protein,  the  medullary cell  immunoreactivity was 
principally cytoplasmic and did not include the nucleus. Ad- 
sorption with the peptide eliminated the medullary staining 
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body recognizes VMAT1 by West- 
ern blot analysis. 25/zg of protein 
from a  membrane preparation  of 
wild-type CHO cells,  CHO cells 
stably  transfected  with  VMAT1 
and  selected  in  MPP  + (MP/~'), 
and  wild-type  PC12 cells  were 
separated  by  electrophoresis 
through 10% polyacrylamide-SDS 
containing  6  M  urea,  blotted  to 
nitrocellulose,  stained  with  the 
anti-peptide VMAT1 antibody at a 
dilution of 1:2,000, and the reac- 
tion  visualized  by  chemi-lumi- 
nescence  (Amersham  Corp.). 
Transfected CHO cells contain ex- 
tremely  large amounts of an  ap- 
proximately  55-kD  protein  (ar- 
row) as well as higher molecular 
weight  forms  whereas  wild-type 
CHO cells contain no immunore- 
active material. PC12 cells contain 
smaller  amounts of the  ~55-kD 
protein (arrow) as well as higher 
molecular weight forms that vary 
in intensity. 
(Fig. 3 b). The origin of  the cortical staining remains unclear 
and was occasionally but not always reduced by peptide ad- 
sorption as well. 
Localization of VMAT1 to Endocytic Vesicles 
in Transfected ClIO Cells 
The transfection of cDNAs for synaptic vesicle proteins into 
nonneural cells has led to their localization at a number of 
characteristic intracellular sites. Heterologous expression of 
synaptophysin in CHO fibroblasts results in protein localiz- 
ing to vesicles that concentrate at the microtubule organizing 
center; this staining co-localizes with the transferrin recep- 
tor that marks a population of recycling microvesicles (John- 
ston et al.,  1989;  Cameron et al.,  1991).  In contrast, the 
vesicle protein synaptotagmin appears at the plasma mem- 
brane when expressed in CHO cells (Feany et al.,  1993). 
The demonstration of vesicular amine transport activity in 
membranes prepared from transfected CHO cells (Liu et al., 
1992b) suggested that the transporter localizes to intracellu- 
lar vesicles containing a vacuolar H+-ATPase and so resem- 
bles  the  targeting  of  synaptophysin  rather  than  synap- 
totagmin. 
In  MPP+-resistant CHO cells,  the particulate pattern of 
glyoxylic  acid-induced fluorescence after loading with exog- 
enous dopamine suggests the presence of  VMATI in intracel- 
lular vesicles (Liu et al.,  1992a). Immunostaining with the 
antibody  to  VMAT1  supported  this  impression  (Fig.  4). 
Double-staining with an antibody to tubulin further indi- 
cated that the peri-nuclear site of protein accumulation coin- 
cides with the microtubule organizing center (Fig. 4, b and 
c) and double staining with WGA demonstrated substantial 
steady-state expression in the vicinity of the Golgi complex 
(Fig.  4,  e  and f).  To determine whether the amine trans- 
porter specifically localizes to a population of recycling vesi- 
cles, we incubated the living cells with human transferrin 
conjugated to Texas red for 30 min and then stained the cells 
for the transporter. Colocalization of  the tagged human trans- 
ferrin with  the  immunoreactive transport  protein  strongly 
supported the presence of the transporter in a population of 
recycling vesicles (Fig.  5).  Sucrose density gradients also 
demonstrated  the  coincidence  of vesicles  containing  the 
transferrin receptor with those containing the amine trans- 
porter (data not shown). Thus, the heterologous expression 
of VMAT1  in CHO cells results in targeting of the trans- 
porter in a manner similar to that of other neuronal vesicle 
proteins such as  synaptophysin and SV2 (Johnston et al., 
1989; Cameron et al., 1991) and differs from the localization 
previously reported for synaptotagmin (Feany et al., 1993). 
The results further indicate that the vesicular amine trans- 
porter contains by itself the signals for sorting to the endo- 
cytic pathway and does not rely on association with another 
synaptic vesicle protein.  Sorting to a  population of acidic 
vesicles thus allows functional expression of the transporter 
in a nonneural cell line. 
Localization of VMATI in PC12 Cells to Large Dense 
Core Vesicles 
To  determine the  intracellular localization of VMAT1  in 
neuro-endocrine cells that store monoamines, we have exam- 
ined the distribution of the endogenous protein expressed by 
PC12 cells. As noted above, the anti-VMAT1 antibody recog- 
nizes  the  vesicular amine  transporter expressed by  these 
cells. Further, these typically round cells can be treated with 
NGF to induce the formation of neural processes and  so 
facilitate intracellular localization. Immunostaining with the 
antibody to VMAT1  shows  predominant expression of the 
antigen in the ends of  processes (Fig. 6), with relatively little 
staining in the cell bodies. To determine the relationship of 
this  immunoreactivity  to  dense  core  granules,  we  have 
stained the same cells with an antibody to secretogranin I, 
a soluble protein of LDCVs, and found the same pattern of 
distribution  in  the  tips  of processes.  Thus,  VMAT1  co- 
localizes with secretogranin I.  Since previous studies have 
demonstrated  the  differential  distribution  of LDCVs  and 
SLMVs  in  NGF-treated PC12  cells  (Schweitzer and Pad- 
dock, 1990), we performed similar double-staining with an- 
tibodies to VMAT1  and the synaptic vesicle protein synap- 
tophysin, which appears at much higher levels in SLMVs 
than in dense core granules (Navone et al., 1986). In contrast 
to  secretogranin,  immunostaining  of  NGF-treated  PC12 
cells with the antibody to synaptophysin showed expression 
predominantly in cell bodies and to a lesser extent at the ends 
of  processes. Staining of  the same cells with the anti-VMAT1 
antibody indicated a  distinct pattern of distribution,  with 
most expression in the processes. Thus, the morphologic ex- 
amination of PC12 cells by light microscopy indicates ex- 
pression of VMAT1  in dense core granules and suggests its 
relative exclusion from SLMVs. 
To  characterize  further  the  subcellular  distribution  of 
VMATI in PC12 cells, we have also fractionated the cells by 
equilibrium sedimentation through sucrose density gradients 
(Schweitzer and Kelley, 1985). The dense core granule frac- 
tion was identified by pre-loading the cells with [3H]norepi- 
nephrine (Fig. 7 A). An immunoblot of the fractions stained 
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cells  express  VMAT1.  Sec- 
tions  from  the  rat  adrenal 
gland  were  stained  with  the 
anti-peptide  antibody  to 
VMAT1 (a) and with the same 
antibody after adsorption with 
the peptide used to generate it 
(b).  All  cells  in  the  adrenal 
medulla (arrows)  but none in 
the cortex react with the anti- 
body.  Adsorption  with  the 
peptide eliminates the medul- 
lary  immunoreactivity  en- 
tirely  and  reduces  the  punc- 
tate  staining  observed  to 
varying degrees in the cortex. 
Bar, 150 #m. 
with an antibody to secretogranin II indicated that this pro- 
tein resides as expected in the heavier, dense core granules 
also  pre-labeled  with  [3H]norepinephrine  (Fig.  7  B).  In 
contrast,  an  antibody  to  synaptophysin  labeled 'predomi- 
nantly a lighter fraction of vesicles distinct from the peak of 
soluble protein, with variable but substantially lower levels 
of  expression  in  the  dense  core  granule  fraction.  The 
anti-peptide antibody to VMATI detected the 55-kD form 
of the protein in the peak of LDCVs centered at fraction 6. 
No  immunoreactive  protein  of this  size  appeared  in  the 
lighter  fractions.  However,  the  immunoreactive  material 
migrating  at  ,,o120 kD  appeared  in  both  heavy and  light 
membrane fractions. To determine whether this material is 
VMAT1  or unrelated  background,  we immunostalned an- 
other Western blot containing  fractions from the gradient 
with a preparation of antibody that had been adsorbed with 
the peptide used to generate it. Pre-adsorption with the pep- 
tide  abolished the  staining  of both the  55-  and  ,,ol20-kD 
bands, indicating that both of these species contain VMATI. 
Thus, the endogenous vesicular amine transporter expressed 
by PC12 cells occurs in two forms, a low molecular weight 
form that  appears  to  reside  exclusively in  LDCVs  and  a 
higher molecular weight form that predominates in dense 
fractions  but  also  occurs  in  lighter  membranes,  possibly 
The Journal of Cell Biology, Volume  127, 1994  1424 Figure 4. VMAT1 immunofluorescence in transfected CHO fibroblasts co-localizes with the microtubule-organizing center and the Golgi 
complex. Stable CHO transformants expressing VMATI were viewed by phase contrast (a and d) and immunostained.with the polyclonal 
rabbit VMAT1 antibody (b and e), a mouse monoclonal antibody to tubulin (c) and WGA conjugated to Texas red (f). For double staining 
of the two sets of cells (a-c and d-f), the VMAT1 rabbit antibody was visualized with a secondary antibody conjugated to fluorescein 
and the mouse anti-tubulin  antibody with a secondary antibody conjugated to Texas red. The strong punctate peri-nuclear  VMAT1 im- 
munoreactivity (arrows, b) co-localizes with the microtubule organizing center (arrows, c). Additional peri-nuclear VMAT1 staining (ar- 
rows, e) co-localizes with wheat germ agglutinin (arrows, f). Bar, 10 #m. 
SLMVs or plasma membrane vesicles. The higher molecular 
weight form usually but not always (Fig. 2) predominates in 
PC12 cells, independent of the method of analysis (by West- 
ern  blot  of cell  homogenates  or  immunoprecipitation  of 
metabolically labeled cell extracts). However, the high mo- 
lecular weight form does not simply occur as soluble protein 
since it had a higher density distinct from the peak of soluble 
protein that appeared at the top of the gradient. 
Large membrane proteins, particularly those with multi- 
ple predicted transmembrane domains,  have a tendency to 
aggregate,  possibly  accounting  for  the  higher  molecular 
weight form of VMAT1  observed in PC12 cells.  However, 
preparation of the extracts from transfected CHO cells under 
the identical conditions did not yield the same species, sug- 
gesting that a modification specific to PC12 cells is responsi- 
ble for this form. To characterize this modification further, 
we metabolically labeled both CHO and PC12 cells, immu- 
noprecipitated  VMAT1  from  the  postnuclear  supernatant 
and  treated  the  precipitates  with  N-glycanase to  remove 
N-linked carbohydrate. As expected from the immunoblots, 
wild-type CHO cells expressed no detectable VMAT1 (Fig. 
8)  whereas  the  MPP+-resistant  CHO  transformants  ex- 
pressed  proteins  of  ,055  and  ,095  kD.  Treatment  with 
N-glycanase reduced both of these to a species migrating at 
,040 kD. The immunoprecipitate from PC12 cells also con- 
tained small amounts of a protein of ,055 kD in addition to 
larger amounts of the  ,0120-kD protein seen on immuno- 
blots.  Interestingly,  treatment  of  this  immunoprecipitate 
with N-glycanase resulted in increased amounts ofa ,050-kD 
protein. This indicated that the high molecular weight form 
of VMAT1  expressed in PC12 cells does not represent ag- 
gregates but rather extensive N-linked carbohydrate modi- 
fication.  Pulse-chase  studies  confirm a  precursor-product 
relationship between the two forms (Liu, Y., and R. H. Ed- 
wards, manuscript in preparation). The failure to reduce the 
proteins in PC12 cells to the size obtained after digestion of 
the proteins expressed in CHO cells further suggests either 
incomplete digestion or a second modification not removed 
by N-glycanase. The treatment of PC12 cells with tunicamy- 
cin also showed reduction of the principal  species to only 
,,050 kD (data not shown),  suggesting that a  second modi- 
fication is responsible. We have identified a similar high mo- 
lecular weight form of the transporter in Western blots of 
protein  extracted  from  the  rat  adrenal  gland  (data  not 
shown),  indicating  that  this  modification  is  not  unique  to 
PC12 cells and occurs in vivo as well. 
Both Endosomes and Synaptic-like Microvesicles 
Contain Small Amounts of VMAT1 
Quantitation  of immunoblots  by  densitometry  shows  that 
65% VMAT1 occurs in LDCVs and 19% in lighter fractions. 
This preferential localization to LDCVs differs from that of 
other membrane proteins that occur in both compartments. 
In contrast to VMAT1, 42 % SV2 immunoreactive protein re- 
sides  in  LDCVs  and  49%  in  lighter  fractions  (data  not 
shown).  To localize the VMAT1 immunoreactivity that ap- 
pears in lower density fractions on the sucrose gradient, we 
have used additional  density gradients.  Light vesicle frac- 
tions  from the  sucrose  gradient  may contain  endosomes, 
SLMVs or both.  To determine whether VMAT1 occurs on 
endosomes as well as LDCVs, we have used sedimentation 
Liu et al. Vesicular Transporter in Secretory Granules  1425 Figure 5. VMAT1 immunofluorescence  co-localizes with a popula- 
tion of recycling endocytic vesicles. Stable CHO transformants ex- 
pressing VMAT1 were pre-incubated with human transferrin con- 
jugated to Texas red for 30 min and immunostained for VMAT1. 
Visualization of VMAT1 immunoreactivity with a secondary anti- 
body conjugated to fluorescein (a) shows a virtually identical pat- 
tern of labeling to the transferrin receptor (b) as a marker of recy- 
cling endocytic vesicles. Bar, 10 ttm. 
through  metrizamide.  Fig.  9  shows  that  on this  gradient 
LDCVs containing secretogranin II sedimented more rapidly 
than endosomal membranes containing the transferrin recep- 
tor and SLMVs expressing synaptophysin. VMATI appeared 
at both sites in the gradient,  reflecting localization to the 
more rapidly sedimenting LDCVs and by a  lighter vesicle 
fraction, either SLMVs or endosomes. Lighter membranes 
contain virtually no secretogranin II,  presumably because 
the  soluble  contents  of LDCVs  are  secreted  rather  than 
recycled. 
To separate endosomes from SLMVs,  we used velocity 
sedimentation through glycerol (Fig.  10).  Using this  gra- 
dient,  transferrin  receptor,  secretogranin  and  pre-loaded 
[3H]norepinephrine localized to the bottom of the gradient 
whereas a peak of synaptophysin was present in the middle. 
Thus,  SLMVs  do  not  sediment  as  rapidly  as  endosomes 
and  LDCVs  in  this  gradient.  A  fraction  of VMAT1  co- 
sedimented with  synaptophysin, indicating localization on 
SLMVs. The analysis of VMAT1  localization in CHO cells 
and the study of other vesicle proteins would predict sig- 
nificant targeting of VMAT1 to endosomes; these gradients 
are consistent with such a localization although they do not 
explicitly prove it. 
Nonspecific monoamine uptake or uptake by a transport 
protein distinct from VMAT1  may mediate storage in vesi- 
cles that do not express VMAT1. To examine this possibility, 
we have used the antibody to VMAT1 to isolate vesicles from 
PC12 cells pre-incubated with [3H]norepinephrine. If vesi- 
cles  that  do  not  contain  VMAT1  store  monoamines,  we 
would only be able to immunoisolate a fraction of the total 
stored radioactivity using this antibody. As a positive con- 
trol, we used the vesicle membrane protein SV2 which oc- 
curs  on both  LDCVs  and  SLMVs  (Schweitzer and  Kelly, 
1985). The monoclonal antibody to SV2 immunoisolates all 
of  the radiolabeled transmitter in the preloaded vesicles (Fig. 
11). The VMAT1  antibody also precipitated essentially all 
the [3H]norepinephrine contained in vesicles, excluding up- 
take into a distinct compartment. 
lmmunoelectron Microscopic Localization of VMATI 
in ChromaJfin  Granules 
To determine the subcellular distribution of VMAT1 in vivo, 
we have used immunoelectron microscopy. Fig.  12  shows 
labeling  of the  rat  adrenal  medulla  with  the  antibody  to 
VMAT1  visualized with peroxidase.  The antibody-labeled 
chromaffin granules but not the nucleus, early Golgi com- 
plex or mitochondria. At higher resolution (Fig. 13), the an- 
tibody also  labeled the endoplasmic  reticulum and trans- 
Golgi network. Thus, immunoreactivity for VMAT1 occurs 
at  several sites  in the  secretory pathway but most promi- 
nently in the chromaffin granules, supporting the results in 
PC12  cells.  Sympathetic nerve fibers entering the adrenal 
medulla contain occasional LDCVs and abundant small clear 
vesicles that do not react with the antibody (Fig.  13 b). In 
contrast to the sympathetic innervation of other peripheral 
tissues,  sympathetic  innervation  of the  adrenal  gland  in- 
volves direct projection of the preganglionic neuron to the 
target without an intervening post-ganglionic neuron. Since 
pre-ganglionic  neurons  use  acetylcholine as  their  neuro- 
transmitter rather than monoamines, sympathetic nerve ter- 
minals within the adrenal gland would not be expected to ex- 
press  a  vesicular amine  transporter.  In addition,  we have 
found  that  post-ganglionic  sympathetic  neurons  express 
VMAT2  rather  than VMAT1  (D.  Peter, C.  Sternini,  N. 
Brecha, and R.  H. Edwards,  preliminary observations). 
Discussion 
Using an antibody raised against the COOH terminus of the 
vesicular amine transporter expressed in the adrenal gland, 
we have localized the protein in transfected CHO fibroblasts 
to  a  population  of recycling  endocytic  vesicles.  By  im- 
munofluorescence, the transporter co-localizes with  recy- 
cling transferrin receptors. In addition, peri-nuclear staining 
co-localizes with markers  for the  microtubule organizing 
The Journal of Cell Biology,  Volume 127, 1994  1426 Figure 6. Endogenous VMAT1 immunofluorescence in PC12 cells co-localizes with LDCVs rather than SLMVs. PC12 cells were treated 
with NGF (10 ng/ml) for 4 d before staining. Three sets of cells (a-c, d-f and g-i) were viewed by phase contrast (a, d, and g), stained 
with the rabbit VMATI antibody (b and e) and the same antibody after adsorption with the peptide used to generate it (h) and the reactions 
visualized with a secondary antibody conjugated to fluorescein. The same cells were double-stained  with a mouse monoclonal antibody 
to secretogranin  I (c and i) and synaptophysin (f). VMAT1 appears predominantly at the tips of neuritic processes  rather than the cell 
body and control serum shows no immunoreactivity (h). Further, VMAT1 co-localizes with secretogranin  I (c), a marker for LDCVs. In 
contrast,  VMAT1 staining appears distinct from synaptophysin (f), a marker for SLMVs. Bar, 10 #m. 
center and the Golgi complex. The results account for the de- 
tection of vesicular amine transport activity in membranes 
prepared from the stable VMAT1 transformants even though 
these cells lack a  known secretory compartment for regu- 
lated release such as synaptic vesicles or LDCVs. Transport 
activity  depends  on  a  H÷-electrochemical gradient  across 
the  vesicle membrane and  several of the compartments in 
which the transporter apparently occurs such as the endo- 
somes and  Golgi complex contain  a  vacuolar H÷-ATPase 
that can generate such a  gradient (Rudnick,  1986;  Forgac, 
1989). 
The sorting of VMATI in CHO cells Strongly resembles 
that of other synaptic vesicle proteins such as synaptophysin 
when they are expressed in fibroblasts (Johnston et al., 1989; 
Cameron et al.,  1991).  These observations indicate that the 
vesicular amine transporter contains its own signals for en- 
docytosis. Recycling of the transporter from the cell surface 
after exocytotic fusion therefore does not require association 
with other synaptic vesicle proteins. Indeed, the expression 
of other synaptic vesicle proteins in CHO fibroblasts appears 
to result in distinct patterns of localization.  In contrast to 
synaptophysin,  synaptotagmin targets to the plasma mem- 
brane and SV2 targets to a  population of vesicles that ex- 
cludes the transferrin and low density lipoprotein receptors 
as markers of the recycling endosomal pathway (Feany et al., 
1993). Interestingly, the vesicular amine transporter resem- 
bles synaptophysin more than these two other synaptic vesi- 
cle proteins in terms of targeting in CHO cells even though 
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Figure 7. Distribution  of VMAT1 by equilibrium  sucrose density gradient fractionation of PC12 cells. PC12 cells were pre-loaded overnight 
with  [3H]norepinephrine  and a postnuclear supernatant loaded onto a 0.6-1.6 M continuous sucrose  gradient, with fractions  collected 
from the bottom. (A) Distribution of total protein on the gradient shows two peaks, one centered at fraction 6 and the other at fraction 
18. Radioactivity also accumulates in a peak centered at fraction 6 that presumably contains LDCVs. (B) Western blot analysis of the same 
fractions  shown in A for VMAT1, secretogranin II, and synaptophysin,  as described  in Fig. 2. VMAT1 localizes with secretogranin  to 
LDCVs whereas  synaptophysin occurs predominantly in lighter membranes (but not soluble proteins as shown in A). VMAT1 occurs  in 
two forms, the ~55-kD form also seen in CHO cells and a higher molecular weight form not seen in CHO cells.  The high molecular 
weight form predominates  in the heavier membrane fractions  and is the only form seen in lighter fractions. 
Figure 8.  VMAT1 contains variable  but substantial amounts  of 
N-linked glycosylation.  Wild type and transfected  (MPP  ~s) CHO 
cells and PC12 cells were metabolically labeled with [35S]cysteine 
and methionine overnight and the postnuclear supernatants immu- 
noprecipitated  with the VMAT1 antibody. The immunoprecipitates 
were then digested without and with N-glycanase and separated by 
electrophoresis as described in Fig. 2. Wild-type  CHO cells contain 
no immunoprecipitated protein whereas  stable  VMAT1 transfor- 
mants contain the '~55- and ~100-kD proteins seen on Western 
blots.  Treatment with N-glycanase  reduces  the majority of these 
species to *40 kD. The unusually  high mobility  of this protein both 
before  and particularly after  N-glycanase  digestion  presumably 
reflects the anomalous electrophoretic behavior of an extremely hy- 
drophobic protein rather than degradation.  In PC12 cells, the high 
molecular weight form  predominates  over a faint but detectable 
band  at  '~55  kD  and  is  reduced  to  ~50  kD  by  N-glycanase 
(arrows). 
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Figure 9.  VMAT1 occurs predominantly on fractions correspond- 
ing to LDCVs. A  post-nuclear supernatant of PC12 cells  prela- 
beled with [3H]norepinephrine was fractionated  by sedimentation 
through metrizamide and the fractions collected from the bottom. 
The upper panel shows the percentage of metrizamide in each frac- 
tion and the middle panel the total protein and radioactivity in each 
fraction.  The lower panel shows the densitometric quantitations of 
VMAT1, secretogranin II (Sgll),  transferrin receptor (TfR), and 
synaptophysin (P38) immunoreactivity  from dot blots stained with 
the appropriate  antibodies.  The immunoreactivity for each of the 
fractions  stained with one antibody was added and the percentage 
of the total in each fraction is shown.  Secretogranin II and [3H]- 
norepinephrine label a broad peak of LDCVs centered  at fraction 
7. VMAT1 labels this same broad peak but also occurs  in lighter 
membrane fractions containing  the transferrin receptor and synap- 
tophysin as markers for endosomes and SLMVs respectively. 
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Figure 10. VMAT1 occurs on SLMVs by glycerol velocity gradient 
fractionation.  PC12 cells were pre-labeled with [3H]norepineph- 
rine,  a postnuclear supernatant sedimented through glycerol and 
the fractions collected from the bottom. The top panel shows the 
percentage of glycerol in each fraction. The middle panel shows to- 
tal protein and radioactivity while the bottom panel indicates per- 
centage of total  immunoreactivity for each of the antibodies de- 
scribed in Fig. 9. VMAT1 roughly co-localizes with synaptophysin 
(P38)  in  lighter  membrane  fractions,  indicating expression  in 
SLMVs. VMAT1 also occurs in heavier membrane fractions that 
contain  LDCVs as  indicated by the  [3H]norepinephrine and  se- 
cretogranin II. 
sorting of the transporter and synaptophysin differ strongly 
in neuro-endocrine PC12 cells. 
In PC12 cells, previous work using the measurement of 
transport activity has suggested localization of the vesicular 
amine transporter in LDCVs (Bauerfeind et al.,  1993). We 
have now used an antibody to  identify preferential local- 
ization of the transport protein in LDCVs both by immu- 
nofluorescence analysis of doubly stained cells and by cell 
fractionation using a variety of gradients. Immunoelectron 
microscopy of adrenal medullary cells also shows staining of 
chromaffin granules but the paucity of SLMVs in these cells 
makes it difficult to exclude a presence in that compartment 
as well. In addition, PC12 ceils may contain more LDCVs 
than SLMVs but the substantial expression of other synaptic 
vesicle membrane proteins such as SV2 and synaptotagmin 
in both compartments (Buckley et al.,  1985;  Walch-Soli- 
mena et al.,  1993) or such as synaptophysin predominantly 
in SLMVs (Navone et al., 1986) makes the preferential local- 
ization of the amine transporter in LDCVs unique. The bio- 
genesis of LDCVs and synaptic vesicles differ in several im- 
portant respects. LDCVs in neurons and secretory granules 
in endocrine cells originate from the trans-Golgi  network 
(Burgess and Kelly,  1987;  Trimble et al.,  1991).  Selected 
proteins  such  as  neural  peptides  sort into  this  regulated 
secretory  pathway  through  poorly characterized  mecha- 
nisms. After fusion with the plasma membrane, components 
of  the dense core granule membrane may recycle to the Golgi 
Figure  11.  Immuno-isolation  of pre-loaded  [3H]norepinephrine 
with the antibody to VMAT1. PCI2  cells were pre-labeled with 
[3H]norepinephrine  and a post-nuclear supernatant incubated with 
S.  aureus  cells pre-coated with the  antibody to VMAT1 and a 
monoclonal antibody to the  vesicle proteoglycan SV2  (stippled 
bars).  Both the VMAT1 and SV2 antibodies isolate all the [3H]- 
norepinephrine  pre-loaded  into  vesicles  as  measured  by  sedi- 
menting all the cellular membranes at high speed (total). Staphylo- 
coccus cells pre-coated with control rabbit serum in the case of 
VMAT1 and control mouse serum in the case of SV2 (open bars) 
precipitated  substantially  less  of  the  pre-loaded  [3H]norepi- 
nephrine. 
complex for refilling and re-release.  In  contrast,  synaptic 
vesicles from neurons or SLMVs from endocrine cells ap- 
pear to originate from early endosomes (Kelly, 1991).  The 
synaptic vesicle protein synaptophysin occurs at only very 
low levels in dense core granules (Navone et al., 1986), sug- 
gesting  that synaptic vesicles do not derive from recycled 
granule membrane components (Cutler and Cramer, 1990). 
Rather,  synaptophysin travels directly to the plasma mem- 
brane  in  the  constitutive  secretory pathway  and  synaptic 
vesicles appear to bud off early endosomes (Clifi-O'Grady 
et al.,  1990; Regnier-Vigouroux et al.,  1991). Thus, LDCVs 
derive from the  regulated  secretory pathway and  SLMVs 
from the constitutive secretory pathway. The mechanism for 
sorting of proteins into these two pathways remains unclear. 
However, membrane proteins such as synaptophysin serve to 
distinguish SLMVs from LDCVs and may enable dissection 
of the relevant sorting signals.  On the other hand,  LDCVs 
contain soluble proteins and membrane-associated proteins 
absent from the constitutive pathway and synaptic vesicles. 
These proteins may sort into the regulated pathway through 
aggregation but a clear sorting signal has not been identified 
(Burgess and Kelly, 1987). However, VMAT1  now provides 
a clear membrane protein uniquely associated with LDCVs 
and not SLMVs. 
In addition to neural peptides, several membrane proteins 
localize preferentially to LDCVs rather than to synaptic vesi- 
cles or SLMVs.  These proteins include cytochrome b561 
that mediates the reduction of intravesicular ascorbate, the 
processing  enzyme peptidylglycine c~-amidating  monoox- 
ygenase (PAM), and dopamine/3-hydroxylase (DBH). DBH 
does not contain a membrane-spanning domain but associ- 
ates with the lumenal face of the vesicle membrane, exclud- 
ing the possibility of sorting signals on the cytoplasmic sur- 
face of the vesicle. PAM occurs in two forms, one soluble 
and  the  other  attached  to  the  vesicle  membrane  at  the 
COOH-terminus  (Milgram  et  al.,  1993,  1994).  The  two 
Liu et  al.  Vesicular Transporter in Secretory Granules  1429 Figure 12.  VMAT1 localizes to chromaftin cells exposed to the reagents for immunolabeling. Electron micrographs of chromaflin cells 
in the adrenal medulla (a) immunolabeled for VMAT1 and (b)  not exposed to the immunoreagents.  The most prominent immunolabel- 
ing in a  occurs in chromaffin granules (curved arrows). Immunoreaction product is notably absent from the chromatfin cell nucleus (N) 
and from axon terminals (t) of adjacent neurons.  In b,  the pattern of immunolabeling seen in a  is absent from tissue not exposed to the 
reagents.  (L,  lysosome; m, mitochondria.  Bar, 2  #m. 
The Journal of Cell Biology, Volume 127, 1994  1430 Figure 13.  VMAT1  immunoreactivity localizes to chromafiin granules and not the synaptic vesicles of adjacent neuronal processes. (a) 
Electron micrograph showing immunoperoxidase reaction product for VMAT1 in most chromaflin granules (curved arrows). Less conspicu- 
ous labeling for VMAT1 occurs in smaller vesicles in the trans-Golgi network (/arge arrows) and in both endoplasmic reticulum and free 
polyribosomes (small arrows). In contrast, immunoreaction product for VMAT1 cannot be detected in mitochondria (m) or early Golgi 
apparatus (G). (b) Higher magnification electron micrograph of the boxed region in Fig. 12 a. Intense labeling for VMAT1 occurs in a 
large population of chromaffin granules (curved arrows), but cannot be detected in either the small clear vesicles (scv) or the dense core 
vesicles (dcv) of adjacent axon terminals. (N, nucleus of chromaftin cell; open arrow,  outer membrane of chromaffin cell. Bar, 0.5 t~m. 
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to LDCVs, indicating  the importance of interactions  within 
the interior of the vesicle for targeting to this pathway. It also 
remains unclear whether PAM occurs in synaptic  vesicles. 
Cytochrome b561 has six predicted transmembrane  domains 
(Perin et al., 1988; Kent and Fleming, 1990) and thus differs 
from DBH and PAM in its membrane topology. Although the 
cytochrome appears  in both  LDCVs  and synaptic  vesicles 
(Walch-Solimena et al., 1993), it is predominantly localized 
to the SLMV peak, suggesting that the vesicular amine trans- 
porter may be a more specific integral membrane protein for 
the regulated  secretory pathway. 
The transporter  may  resemble soluble proteins that are 
specific for LDCVs and sort into the pathway  through  lu- 
menal domains. Recent evidence suggests that interactions of 
this type may confer sorting  to the apical pathway in pola- 
rized epithelial cells (Fiedler et al., 1994). The identification 
of extensive  N-linked glycosylation  on the transporter  ex- 
pressed in PC12 cells but not fibroblasts  further raises the 
possibility of interaction  with lectins that may play a role in 
polarized targeting.  However, sorting may also occur by in- 
teraction of the transmembrane  and cytoplasmic  domains 
with specific proteins of a protein sorting machinery. 
Velocity gradient centrifugation through glycerol indicates 
that a relatively small proportion of the total vesicular amine 
transporter occurs in SLMVs. The small amounts of protein 
may account for the failure to observe vesicular amine trans- 
port activity  in SLMVs  prepared  on  sucrose density  gra- 
dients, particularly  when adjacent  fractions containing en- 
dosomes express substantial transport activity (Bauerfeind et 
al.,  1993).  The transporter  could appear in SLMVs by two 
distinct mechanisms.  First, incomplete sorting  to the regu- 
lated pathway could result  in some of the transport  protein 
reaching the cell surface through  the constitutive pathway. 
Second,  the transporter  could arrive  at the plasma mem- 
brane  following the  fusion of LDCVs.  In  both  cases,  the 
transporter  may  sort  into  SLMVs  after  endocytosis.  Al- 
though the amine transporter  in SLMVs represents  a small 
fraction of the total transporter in PC12 cells, neurons in the 
central nervous system appear to store monoamines in small 
synaptic vesicles (Smith, 1972; Thureson-Klein, 1983). The 
identification of small amounts of the adrenal transporter in 
PC12 SLMVs raises the possibility that central  neurons use 
a similar pathway to sort the transporter  into synaptic  vesi- 
cles. Neurons may simply increase the efficiency of sorting 
to  this  pathway. Alternatively,  the  vesicular  amine  trans- 
porter expressed in the brain may contain signals different 
from the adrenal  transporter  that increase the efficiency of 
this  sorting. 
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